Merus touts bispecific antibody efficacy data with a later data cut-off in uncommon NRG1+ cancers: #ESMO23

Reynald Castañeda

Deputy Editor

MADRID — Merus unveiled further efficacy data on Monday for its bispecific antibody zenocutuzumab, which further demonstrates “robust and durable” response in patients with NRG1+ non …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merus touts bispecific antibody efficacy data with a later data cut-off in uncommon NRG1+ cancers: #ESMO23

Reynald Castañeda

Deputy Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Exclusive: Florida cancer biotech raises $100M Series A

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Merus touts bis­pe­cif­ic an­ti­body ef­fi­ca­cy da­ta with a lat­er da­ta cut-off in un­com­mon NRG1+ can­cers: #ES­MO23

Reynald Castañeda

Deputy Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Merus touts bispecific antibody efficacy data with a later data cut-off in uncommon NRG1+ cancers: #ESMO23

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Exclusive: Florida cancer biotech raises $100M Series A

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.